Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL) (PEARL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00141323
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : August 15, 2011
Information provided by:
Ligand Pharmaceuticals